Genedata Biologics integrated workflow platform used to increase automation of Kymab’s transgenic mice-based discovery platforms
November 17, 2015
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Kymab Ltd. has licensed Genedata Biologics™ for use in their proprietary antibody discovery programs. The platform will support biopharma R&D operations from early B-cell and hybridoma screening, to antibody engineering, expression, purification, and analytics.
“Genedata Biologics is the leading workflow platform for high-throughput antibody discovery. Having access to this platform is expected to enhance Kymab’s capabilities across all our research programs,” said Glenn A. Friedrich, PhD, Chief Operating Officer at Kymab Ltd. “Thanks to Genedata’s flexible business model, we are able to take advantage of Genedata’s unique technology under terms that work well for a company of our size.”
Kymab uses Genedata Biologics for their screening platform to deeply mine the proprietary Kymouse™ antibody repertoire and to identify candidate-quality molecules with exceptionally broad diversity and the quality of fully human antibodies.
“Genedata Biologics makes the antibody discovery and optimization process more efficient. The platform’s open architecture allows us to flexibly configure the system to work with Kymab’s proprietary workflows and technologies, including our transgenic mouse platform,” said David Melvin, PhD, Director of Informatics at Kymab. “We are building our screening, expression, purification, and analytics workflows on the Genedata Biologics platform, which we believe will lead to an increase in throughput and automation.”
“We are delighted that Kymab, a leader in the development of transgenic mouse platforms, is now also taking advantage of the Genedata Biologics platform to further their antibody discovery programs. We see a rapidly growing number of smaller, highly innovative biotech companies like Kymab, who require an integrated workflow platform to manage and streamline their increasingly complex antibody discovery processes,” said Dr. Othmar Pfannes, Chief Executive Officer of Genedata. “We look forward to continue to partner with the best biopharma R&D organizations worldwide.”
In the four short years since its first release in 2011, Genedata Biologics has been rapidly adopted by almost half of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.